Marseille-based Adcytherix, a biopharmaceutical firm creating novel and proprietary antibody drug conjugates (ADC), has raised €105 million in a Collection A financing spherical to advance its lead candidate and deal with excessive unmet want illnesses
The spherical was co-led by Andera Companions, Angelini Ventures, Bpifrance (as a part of each Giant Enterprise and InnoBio funding methods) and Kurma Companions, adopted by Surveyor Capital (a Citadel firm), aMoon and current shareholders Pontifax, DawnBiopharma (a platform managed by KKR), Pureos Bioventures and RA Capital. The transaction represents the primary funding from Andera Companions’ new BioDiscovery 7 fund.
Jack Elands, Chief Govt Officer and Founding father of Adcytherix, commented: “Closing the most important ADC-focused Collection A in Europe in 2025 validates our science, our imaginative and prescient, and the distinctive work of our staff since inception simply 18 months in the past. We’re proud to have attracted a world-class syndicate of traders who share our ambition to develop breakthrough ADCs for sufferers immune to the present lessons of ADCs.”
The Collection A financing of Adcytherix follows different vital bioconjugate and oncology-focused rounds corresponding to yesterday’s Tubulis’s €308 million Collection C to advance its antibody-drug conjugate pipeline from Munich, and Ciloa’s €6.5 million increase in Montpellier to progress engineered exosome therapies.
Collectively, these rounds illustrate sustained investor urge for food for novel biologic modalities in Europe, spanning each antibody-based and vesicle-based therapeutics. Adcytherix’s funding positions it alongside Tubulis inside a dynamic ADC panorama, with each firms increasing European capabilities in focused oncology drug improvement.
Sofia Ioannidou, PhD, Companion at Andera Companions, added: “We’re delighted to make our first funding from the BioDiscovery 7 fund on this landmark transaction. Adcytherix stands out with its deep ADC experience, a differentiated lead programme, and a particular technique centered on novel payload lessons with the potential to each broaden the attain of ADCs to tumors that at the moment reply poorly or in no way to this modality, and to beat resistance mechanisms noticed with generally used payloads.
“We look ahead to supporting Jack and his staff as they construct a next-generation ADC platform able to delivering transformative therapies to sufferers.”
Based in 2024, Adcytherix is a biopharmaceutical firm centered on the event of novel ADC to deal with excessive unmet want illnesses corresponding to most cancers. The corporate was based by Jack Elands and Pontifax Enterprise Capital with two different executives of Emergence Therapeutics, Xavier Preville and Carsten Dehning as Co-founders.
Adcytherix’s ambition is to change into a big impartial ADC powerhouse driving the event of transformational ADC know-how for focused most cancers remedy.
The brand new funding will allow the corporate to advance its lead candidate ADCX-020 into the clinic, with first investigational new drug (IND – US) and medical trial functions (CTA – EU, UK and Canada) filings deliberate by finish 2025.
In parallel, Adcytherix will broaden its pipeline of proprietary ADCs utilizing novel payloads.
Sofia Ioannidou of Andera Companions will even be becoming a member of the Supervisory Committee following the Collection A financing.
